Table 1 Baseline characteristic of 16 patients with eosinophilic granulomatosis with polyangiitis
Pre-MPZ (n = 16) | Post–MPZ (n = 16) | P value* | |
|---|---|---|---|
Clinical manifestations at diagnosis, n (%) | Asthma 16 (100), general 10 (62.5), cutaneous 8 (50.0), ENT 5 (31.3), chest 8 (50.0), cardiomyopathy 3 (18.8), abdominal 1 (6.3), neuropathy 8 (50.0), ANCA positive status 5 (31.3), biopsy findings 12 (75) | ||
Male/female/age at MPZ introduction | 7/9/61.5 [53.3–70.5] | ||
Disease duration (months) at MPZ introduction | 54 [22–144] | ||
Treatment history, n (%) | CS pulse 2 (12.5), high-dose CS 14 (87.5), low-dose CS 2 (12.5), IVCY 9 (56.3), IVIG 6 (37.5), RTX 1 (6.3), MTX 6 (37.5), AZ 12 (75.0), TAC 1 (6.3) | ||
Relapsing/refractory/remission, n (%) | 4 (25.0)/11 (68.7)/1 (6.3) | 10 (62.5)/6 (37.5)/0 (0) | ND |
Concomitant CS dose (PSL mg/day) | 8.0 [5.0–11.5] | 6.5 [2.6–10.0] | 0.2012 |
Concomitant CS < 4 mg/day (PSL), n (%) | 3 (18.8) | 5 (31.3) | 0.1573 |
Concomitant immunosuppressant, n (%) | AZ 6 (37.5), MTX 5 (31.3), TAC 1 (6.3) | AZ 6 (37.5), MTX 4 (25.0), TAC 1 (6.3) | |
Without immunosuppressant, n (%) | 6 (37.5) | 7 (43.8) | 0.3173 |
BVAS | 0 [0–2.0] | 1.0 [0–3.8] | 0.1084 |
BVAS > 0, n (%) | 4 (25.0) | 8 (50.0) | 0.3173 |
BVAS items | Asthma 2 (12.5), sinonasal 2 (12.5), chest 1 (6.3) | Asthma 6 (37.5), general 1 (6.3), cutaneous 2 (12.5), sinonasal 2 (12.5), chest 3 (18.8), | |
VDI | 3.5 [3.0–4.8] | 4.0 [3.0–5.8] | 0.5577 |
VDI items | Chronic bronchial asthma 16 (100), chronic respiratory failure 1 (6.3), abnormal respiratory function 7 (43.8), old myocardial infarction 2 (12.5), cardiomyopathy 2 (12.5), low vision 1 (6.3), chronic sinusitis 6 (37.5), deafness 3 (18.8), peripheral neuropathy 8 (50.0), diabetes 4 (25), hypertension 4 (25), osteoporosis 5 (31.3), other 3 (18.8) | Chronic bronchial asthma 16 (100), chronic respiratory failure 1 (6.3), abnormal respiratory function 8 (50.0), old myocardial infarction 2 (12.5), cardiomyopathy 2 (12.5), low vision 1 (6.3), chronic sinusitis 7 (43.8), deafness 3 (18.8), peripheral neuropathy 8 (50.0), diabetes 4 (25), hypertension 4 (25), osteoporosis 5 (31.3), other 5 (31.3) | |
ANCA-positive status, n (%) | 0 (0) | 1 (6.3) | ND |
Absolute eosinophil count (/μL) | 178.6 [48.7–370.2] | 183 [60.0–2479] | 0.1591 |
CRP (mg/dL) | 0.06 [0.03–0.09] | 0.09 [0.05–0.24] | 0.0593 |